Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05732974

A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse

Early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. There are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Non-small Cell Lung Cancer Stage IIIA Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

This study will use data from an already available cohort of patients enrolled in the Resting study (a project funded by TRANSCAN in 2018) as a training set and data from a new concurrent cohort as validation set.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with an early stage of non small cell lung cancer
  • Indication of surgical resection
  • Patient able to understand and give his consent
  • Patient affiliated to the health insurance

Exclusion criteria

  • Patient with another cancer in the last 5 years
  • Patient with an allergy to the contrast medium
  • Patient under legal protection

Treatment and study plan

Resected non small cell lung cancer

Other

plasma sample, tissue sample and computed tomography scan images

Primary outcomes

  1. Algorithm for disease free survival

    Time frame: 18 months

    Analysis on a training cohort of resected early-stage non small cell lung cancer

Study contacts

Contact information is provided by the study sponsor or research team.

Julien MAZIERES, MD, PhD

CONTACT

[email protected]

0567771837 ext. 33

Sponsors and collaborators

Lead sponsor

University Hospital, Toulouse

Other

Registry information

Acronym: MIRACLE

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Feb 17, 2023
Registry last updated
Sep 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.